Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
In Silico and in Vitro Evaluation of a Recombinant Fusion Peptide As a Novel Candidate Vaccine for Egfr-Positive Tumors Publisher



Asadighalehni M1 ; Rasaee MJ2 ; Khosravani M3 ; Bazl MR4 ; Mohamadi M1 ; Fatemi F1 ; Sadroddiny E1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  3. 3. Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Biosciences Biotechnology Research Asia Published:2015


Abstract

The epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor tyrosine kinases (RTK). EGFR over expressed in different cancers like neck, lung and breast. Various approaches have been used to activate the immune system against EGFR+ cancer such as vaccine therapy. Herein a recombinant fusion peptide composed of EGFR mimotope and L2 domain of EGFR designed. Using in silico studies the potency of the peptide as a vaccine evaluated. This peptide was then cloned into an expression vector and expressed in E. Coli. The ELISA results of the purified peptide against anti EGFR antibodies showed that this peptide could be functional as a vaccine candidate against EGFR-positive tumors.